WFDC2 and ovarian cancer: A novel localized SPR biosensor is also developed for recognizing the HE4 biomarker from ovarian cancer patients, by which the anti-HE4 antibody is used as a probe and assembled on the surface of nanochip to distinctly recognize the HE4 antigen [122].